We are rapidly transitioning to an innovation and R&D-driven pharmaceutical company, with a mission of “providing today’s patients with medicines of the future.” We focus on oncology, central nervous system disease and autoimmune disease therapeutic areas.We have established R&D centers in Shanghai, Nanjing and Boston. With the approval of the Ministry of Science and Technology, we have also established a National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals . We have been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China” and “Top 100 Pharmaceutical Manufacturing Enterprises of China ”. We were listed on the Hong Kong Stock Exchange in 2020.
Location: China, Jiangsu, Meiyuan Xincun
Employees: 5001-10000
Founded date: 1995
Investors 2
| Date | Name | Website |
| - | Lake Bleu ... | lakebleu-c... |
| - | Hony Capit... | honycapita... |
Mentions in press and media 16
| Date | Title | Description | Source |
| 27.02.2024 | Biopharma firm Simcere Zaiming pockets $134.8m in fresh fund... | Simcere Zaiming Pharmaceutical, a subsidiary of Hong Kong-listed branded generic player Simcere Phar... | dealstreet... |
| 14.03.2023 | Simcere Zaiming Announces Clinical Collaboration to Evaluate... | NANJING, China, March 14, 2023 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) (Simce... | en.prnasia... |
| 09.02.2023 | First Prescription for COSELA® (trilaciclib) Issued in China... | - COSELA®, the world's first and only myeloprotection drug, was prescribed in Jilin Cancer Hospital ... | en.prnasia... |
| 20.12.2022 | PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-... | NANJING, China, Dec. 20, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced today... | en.prnasia... |
| 16.11.2022 | Simcere and Idorsia enter into a licensing agreement for dar... | NANJING, China, Nov. 16, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simce... | en.prnasia... |
| 16.11.2022 | Simcere and Idorsia enter into a licensing agreement for dar... | NANJING, China, Nov. 15, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simce... | einpresswi... |
| 27.10.2022 | Simcere Receives FDA Clearance of Investigational New Drug A... | Second US IND approval this year for the global pharmaceutical group NANJING, China and BOSTON, Oct.... | en.prnasia... |
| 06.10.2022 | Simcere agree license deal of $492M USD with Almirall | Almirall Logo Simcere Logo Almirall granted exclusive rights to commercialise SIM0278 for all indica... | einpresswi... |
| 01.10.2022 | Simcere and Almirall Enter into a Licensing Agreement for IL... | Simere and Almirall logo The deal's total amount set a record high, for the out-licensing of preclin... | einpresswi... |
| 29.09.2022 | Simcere and Almirall Enter into a Licensing Agreement for IL... | Simcere will receive a $15 million upfront payment, and up to $492 million in development and commer... | en.prnasia... |
Show more